#4 CLNN Clene posts promising results from mid-stage sclerosis study May 12, 2021 9:14 AM ETClene Inc. (CLNN) Clene (NASDAQ:CLNN) posted results from a mid-stage trial, which showed that the company's treatment CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients. Shares up more than 9% premarket. The Phase 2 RESCUE-ALS trial is evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in the treatment of early symptomatic ALS patients. The data, presented during the European Network to Cure ALS (ENCALS) 2021 Annual Meeting, provide further evidence supporting the disease modifying potential of CNM-Au8 for the treatment of ALS, the company said. The RESCUE-ALS study’s primary efficacy endpoint utilizes Motor Unit Number Index (MUNIX), an electromyography technique that is a sensitive predictor of clinical decline which measures the change in the estimated number of functioning motor neurons serving specific muscle. In the overall study population (n = 45; randomized 1:1 active CNM-Au8 30 mg daily to placebo), 34%, 26%, and 18% of patients who completed Weeks 12, 24, and 36, respectively, showed MUNIX sum increases from baseline. Topline data from the study is expected in the second half of 2021.<---------
Quick lesson in Premium Flower. Raymond Chang Agrify entered 2021 with positive momentum, which drove a strong financial performance for the quarter. And I am extremely pleased to report that we achieved record quarterly company revenue of $7 million for Q1 of 2021, representing a 600% increase over Q1 2020 revenue and a consecutive quarterly increase of 60% from $4.4 million in Q4 of 2020. During the quarter, we have also focused heavily on building our sales pipeline. And we successfully increased our customer backlog by more than 38% to over $82 million from $59 million at the end of Q4 2020. The strong improvement we are seeing in our financial results is driven by the continuous successes we are seeing from our existing customers’ facilities, resulting in not only a growing pipeline of opportunities, but also in customer reengagements for expanded partnership. I am proud to share that as of today, we have expanded our partnerships with every single one of our product customers, with 3 of our 4 legacy customers purchasing additional products and services and the fourth in events discussions. Yes, we are talking about 100% reengagement with all of our customers. This is by far the strongest testimony of Agrify delivering value. And not only are our customers returning, but we are also expanding the scope of our partnership and further aligning our interests while generating high-recurring SaaS and production based success fees. As a result of these new and expanded engagements, we increased the expected annual recurring revenue of our early customers for $1.2 million of annual SaaS to over $10 million of estimated high margin recurring SaaS and production-based success fees. This represents over an 800% increase in the lifetime value of these customers.
the results our customers are experiencing following the implementation of our VFU solution has been outstanding. Data, science and technology drive everything we do at Agrify. For example, one of our clients achieved repeated levels of consistency across multiple strains, across multiple harvest batches, with less than 1% variation in the total cannabinoid profile and less than 0.01% variation in the terpene profile. This consistency, combined with exceptional quality, driven by a model of continuous improvement, allows them to sell their flower for prices 25% plus above the state average. With cannabinoid levels greater than 30% and terpene levels peaking at 5.4%, this client has penetrated the competitive Nevada dispensary landscape, including Planet 13, Green Thumb Industries, and Jardin amongst others. Catching in nearly $500 premium per pound, this client has built a reputation on producing exceptional flower in Agrify VFUs.
Stoney! Happy Sunday night. A new week dawns. Hmmmm. Granny's shorts will be the theme this week. I already have it picked. secret but it closed at $150 A stoney fav to boot. Edit... hey btw Stoney, you spelled Sake wrong. I did too, but only on the cut and paste.
this one might be worth looking into, mostly because it's on the otc so it should pump on news and has a lot of fancy words that sound great and the chart/volume look good....though what the heck is it
here's one i looked into last week: Ecosynthetix Inc 4.70 USD+0.04 (0.77%)today Jun 11, 4:00 PM EDT OTCMKTS: ECSNF It's canadian. They make reneweable chemicals to replace the toxic stuff, replacing things like formaldehyde in manufactured wood furniture. i think ikea was testing them out, but no contract came of it. the chart keeps going up, but when i read over their financial reports, they seemed to be making less money as time was passing.
ok, dug in a second more and stoney most of this is an advertisement paid for by AMMPF. Your post comes from an article yahoo ran that they picked up from oilprice.com. https://finance.yahoo.com/news/3-stocks-watch-hydrogen-boom-220000054.html The fine print at the end of the article: Oilprice.com, Advanced Media Solutions Ltd, and their owners, managers, employees, and assigns (collectively, “Oilprice.com”) are being paid ninety thousand USD for this article as part of a larger marketing campaign for CSE:AMMP. In addition, AMMP has issued 500,000 restricted stock units to Oilprice which will unconditionally convert to common shares after 4 months. The information in this report and on our website has not been independently verified and is not guaranteed to be correct.